TF and COVID-19: Being as FVIIa-AT is an indirect marker of FVIIa-TF interaction, its laboratory evaluation could hence be considered clinically useful in conditions such as COVID-19 characterized by TF upregulation/activation, and where the inhibition of the TF pathway has been hypothesized to exert beneficial effects [44].